Melatonin Augments the Effects of Fluoxetine on Depression-Like Behavior and Hippocampal BDNF–TrkB Signaling

Neuroscience Bulletin

Volumn 34, Issue 2, 2018, Pages 303-311

  Li, Kun ^a   Shen, Si ^a   Ji, Yu Tian ^a   Li, Xu Yun ^a   Zhang, Li San ^b   Wang, Xiao Dong ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

BDNF; Depression; Fluoxetine; Melatonin; TrkB

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CORTICOSTERONE; FLUOXETINE; MELATONIN; ANTIDEPRESSANT AGENT; MEMBRANE PROTEIN; NTRK2 PROTEIN, MOUSE; PROTEIN TYROSINE KINASE;

ADULT; ANHEDONIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ANXIETY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DEPRESSION; DRUG MECHANISM; DRUG POTENTIATION; EXPERIMENTAL BEHAVIORAL TEST; FORCED SWIM TEST; FUR; GROOMING; HIPPOCAMPUS; IMMOBILITY TIME; IMMOBILIZATION STRESS; LATENT PERIOD; LOCOMOTION; MALE; MOUSE; NONHUMAN; OPEN FIELD TEST; PHENOTYPE; PREFRONTAL CORTEX; SIGNAL TRANSDUCTION; SPATIAL MEMORY; SPLASH TEST; WORKING MEMORY; Y-MAZE TEST; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; COMBINATION DRUG THERAPY; DRUG EFFECT; EXERCISE; METABOLISM;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FLUOXETINE; HIPPOCAMPUS; MALE; MELATONIN; MEMBRANE GLYCOPROTEINS; MICE, INBRED C57BL; PROTEIN-TYROSINE KINASES; RESTRAINT, PHYSICAL; SIGNAL TRANSDUCTION;

EID: 85032704114     PISSN: 16737067     EISSN: 19958218     Source Type: Journal    
DOI: 10.1007/s12264-017-0189-z     Document Type: Article

References (48)

1. Seo JS, Zhong P, Liu A, Yan Z, Greengard P. Elevation of p11 in lateral habenula mediates depression-like behavior. Mol Psychiatry 2017. doi:10.1016/j.pbb.2017.02.004.
2. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013, 382: 1575–1586.
3. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 2002, 34: 13–25.
4. Cai S, Huang S, Hao W. New hypothesis and treatment targets of depression: an integrated view of key findings. Neurosci Bull 2015, 31: 61–74.
5. Jans LA, Riedel WJ, Markus CR, Blokland A. Serotonergic vulnerability and depression: assumptions, experimental evidence and implications. Mol Psychiatry 2007, 12: 522–543.
6. Blier P, El Mansari M. Serotonin and beyond: therapeutics for major depression. Philos Trans R Soc Lond B Biol Sci 2013, 368: 20120536.
7. Licinio J, Wong ML. Depression, antidepressants and suicidality: a critical appraisal. Nat Rev Drug Discov 2005, 4: 165–171.
8. Wong DT, Perry KW, Bymaster FP. Case history: the discovery of fluoxetine hydrochloride (Prozac). Nat Rev Drug Discov 2005, 4: 764–774.
9. Kong H, Sha LL, Fan Y, Xiao M, Ding JH, Wu J, et al. Requirement of AQP4 for antidepressive efficiency of fluoxetine: implication in adult hippocampal neurogenesis. Neuropsychopharmacology 2009, 34: 1263–1276.
10. Dubocovich ML, Delagrange P, Krause DN, Sugden D, Cardinali DP, Olcese J. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev 2010, 62: 343–380.
11. Hansen MV, Danielsen AK, Hageman I, Rosenberg J, Gogenur I. The therapeutic or prophylactic effect of exogenous melatonin against depression and depressive symptoms: a systematic review and meta-analysis. Eur Neuropsychopharmacol 2014, 24: 1719–1728.
12. Comai S, Gobbi G. Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology. J Psychiatry Neurosci 2014, 39: 6–21.
13. Croxtall JD, Scott LJ. Olanzapine/Fluiloxietine A Review of its Use in Patients With Treatment-Resistant Major Depressive Disorder. CNS Drugs 2010, 24: 245–262.
14. Hickie IB, Rogers NL. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 2011, 378: 621–631.
15. Yu H, Chen ZY. The role of BDNF in depression on the basis of its location in the neural circuitry. Acta Pharmacol Sin 2011, 32: 3–11.
16. Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med 2016, 22: 238–249.
17. Zhou D, Zhang Z, Liu L, Li C, Li M, Yu H, et al. The antidepressant-like effects of biperiden may involve BDNF/TrkB signaling-mediated BICC1 expression in the hippocampus and prefrontal cortex of mice. Pharmacol Biochem Behav 2017, 157: 47–57.
18. Nemeroff CB, Owens MJ. Treatment of mood disorders. Nat Neurosci 2002, 5 Suppl: 1068–1070.
19. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008, 455: 894–902.
20. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006, 9: 519–525.
21. Guo QH, Tong QH, Lu N, Cao H, Yang L, Zhang YQ. Proteomic analysis of the hippocampus in mouse models of trigeminal neuralgia and inescapable shock-induced depression. Neurosci Bull 2017. doi: 10.1007/s12264-017-0131-4.
22. Liu W, Mao Y, Wei D, Yang J, Du X, Xie P, et al. Structural asymmetry of dorsolateral prefrontal cortex correlates with depressive symptoms: evidence from healthy individuals and patients with major depressive disorder. Neurosci Bull 2016, 32: 217–226.
23. Gelman PL, Flores-Ramos M, Lopez-Martinez M, Fuentes CC, Grajeda JP. Hypothalamic-pituitary-adrenal axis function during perinatal depression. Neurosci Bull 2015, 31: 338–350.
24. Ding K, Xu J, Wang H, Zhang L, Wu Y, Li T. Melatonin protects the brain from apoptosis by enhancement of autophagy after traumatic brain injury in mice. Neurochem Int 2015, 91: 46–54.
25. Ma M, Ren Q, Yang C, Zhang JC, Yao W, Dong C, et al. Adjunctive treatment of brexpiprazole with fluoxetine shows a rapid antidepressant effect in social defeat stress model: Role of BDNF–TrkB signaling. Sci Rep 2016, 6: 39209.
26. Mineur YS, Prasol DJ, Belzung C, Crusio WE. Agonistic behavior and unpredictable chronic mild stress in mice. Behavior Genetics 2003, 33: 513–519.
27. Wang XD, Labermaier C, Holsboer F, Wurst W, Deussing JM, Muller MB, et al. Early-life stress-induced anxiety-related behavior in adult mice partially requires forebrain corticotropin-releasing hormone receptor 1. Eur J Neurosci 2012, 36: 2360–2367.
28. Schmidt MV, Trumbach D, Weber P, Wagner K, Scharf SH, Liebl C, et al. Individual stress vulnerability is predicted by short-term memory and AMPA receptor subunit ratio in the hippocampus. J Neurosci 2010, 30: 16949–16958.
29. Moretti M, Neis VB, Matheus FC, Cunha MP, Rosa PB, Ribeiro CM, et al. Effects of agmatine on depressive-like behavior induced by intracerebroventricular administration of 1-methyl-4-phenylpyridinium (MPP(+)). Neurotox Res 2015, 28: 222–231.
30. Porsolt RD, Anton G, Blavet N, Jalfre M. Behavioral despair in rats - new model sensitive to antidepressant treatments. Eur J Pharmacol 1978, 47: 379–391.
31. Regev L, Neufeld-Cohen A, Tsoory M, Kuperman Y, Getselter D, Gil S, et al. Prolonged and site-specific over-expression of corticotropin-releasing factor reveals differential roles for extended amygdala nuclei in emotional regulation. Mol Psychiatry 2011, 16: 714–728.
32. Wang XD, Chen Y, Wolf M, Wagner KV, Liebl C, Scharf SH, et al. Forebrain CRHR1 deficiency attenuates chronic stress-induced cognitive deficits and dendritic remodeling. Neurobiol Dis 2011, 42: 300–310.
33. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006, 7: 137–151.
34. Hashimoto K, Shimizu E, Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev 2004, 45: 104–114.
35. Zhou WJ, Xu N, Kong L, Sun SC, Xu XF, Jia MZ, et al. The antidepressant roles of Wnt2 and Wnt3 in stress-induced depression-like behaviors. Transl Psychiatry 2016, 6: e892.
36. Griebel G, Simiand J, Steinberg R, Jung M, Gully D, Roger P, et al. 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylp henyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 2002, 301: 333–345.
37. Macedo IC, Rozisky JR, Oliveira C, Oliveira CM, Laste G, Nonose Y, et al. Chronic stress associated with hypercaloric diet changes the hippocampal BDNF levels in male Wistar rats. Neuropeptides 2015, 51: 75–81.
38. Valles A, Marti O, Garcia A, Armario A. Single exposure to stressors causes long-lasting, stress-dependent reduction of food intake in rats. Am J Physiol Regul Integr Comp Physiol 2000, 279: R1138–R1144.
39. Di Liberto V, Frinchi M, Verdi V, Vitale A, Plescia F, Cannizzaro C, et al. Anxiolytic effects of muscarinic acetylcholine receptors agonist oxotremorine in chronically stressed rats and related changes in BDNF and FGF2 levels in the hippocampus and prefrontal cortex. Psychopharmacology (Berl) 2017, 234: 559–573.
40. McEwen BS, Morrison JH. The brain on stress: vulnerability and plasticity of the prefrontal cortex over the life course. Neuron 2013, 79: 16–29.
41. Dulawa SC, Holick KA, Gundersen B, Hen R. Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 2004, 29: 1321–1330.
42. Wernicke JF. Safety and side effect profile of fluoxetine. Expert Opin Drug Saf 2004, 3: 495–504.
43. Souza LC, Filho CB, Fabbro LD, de Gomes MG, Goes AT, Jesse CR. Depressive-like behaviour induced by an intracerebroventricular injection of streptozotocin in mice: the protective effect of fluoxetine, antitumour necrosis factor-alpha and thalidomide therapies. Behav Pharmacol 2013, 24: 79–86.
44. Samuels BA, Anacker C, Hu A, Levinstein MR, Pickenhagen A, Tsetsenis T, et al. 5-HT1A receptors on mature dentate gyrus granule cells are critical for the antidepressant response. Nat Neurosci 2015, 18: 1606–1616.
45. Carman JS, Post RM, Buswell R, Goodwin FK. Negative effects of melatonin on depression. Am J Psychiatry 1976, 133: 1181–1186.
46. Tao W, Dong Y, Su Q, Wang H, Chen Y, Xue W, et al. Liquiritigenin reverses depression-like behavior in unpredictable chronic mild stress-induced mice by regulating PI3K/Akt/mTOR mediated BDNF/TrkB pathway. Behav Brain Res 2016, 308: 177–186.
47. Hoijman E, Rocha Viegas L, Keller Sarmiento MI, Rosenstein RE, Pecci A. Involvement of Bax protein in the prevention of glucocorticoid-induced thymocytes apoptosis by melatonin. Endocrinology 2004, 145: 418–425.
48. Martinowich K, Manji H, Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci 2007, 10: 1089–1093.